SEC Company Response from Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Feb 6, 2020
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Feb. 6, 2020 · CIK: 0001359931 · Accession: 0001104659-20-011789
AI Filing Summary & Sentiment
File numbers found in text: 333-236173
Show Raw Text
CORRESP 1 filename1.htm ArTara Therapeutics, Inc. 1 Little West 12th Street New York, NY 10014 (646) 844-0337 February 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: William Mastrianna Re: ArTara Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-236173 Acceleration Request Requested Date: Monday, February 10, 2020 Requested Time: 4:30 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ArTara Therapeutics, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on Monday, February 10, 2020, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Ryan S. Sansom of Cooley LLP at (617) 937-2335 or Karen E. Deschaine of Cooley LLP at (858) 550-6088. Sincerely, ARTARA THERAPEUTICS, INC. By: /s/ Jesse Shefferman Jesse Shefferman President and Chief Executive Officer